NewEdge Wealth LLC Reduces Holdings in Amgen Inc. $AMGN

NewEdge Wealth LLC lessened its position in shares of Amgen Inc. (NASDAQ:AMGN) by 25.0% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 110,074 shares of the medical research company’s stock after selling 36,663 shares during the quarter. NewEdge Wealth LLC’s holdings in Amgen were worth $39,860,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its position in Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after purchasing an additional 5,226 shares during the period. Sivia Capital Partners LLC lifted its stake in shares of Amgen by 10.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 114 shares during the last quarter. Schnieders Capital Management LLC. grew its holdings in shares of Amgen by 29.3% during the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after purchasing an additional 5,853 shares during the period. Main Street Financial Solutions LLC grew its holdings in shares of Amgen by 11.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock worth $1,141,000 after purchasing an additional 416 shares during the period. Finally, Ieq Capital LLC increased its position in shares of Amgen by 5.1% during the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock worth $15,120,000 after purchasing an additional 2,611 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Up 4.0%

NASDAQ AMGN opened at $442.36 on Thursday. The firm has a 50 day simple moving average of $375.75 and a 200-day simple moving average of $360.76. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. Amgen Inc. has a one year low of $269.77 and a one year high of $443.20. The firm has a market cap of $239.15 billion, a price-to-earnings ratio of 27.49, a PEG ratio of 3.95 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. During the same quarter in the previous year, the business posted $6.02 earnings per share. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities research analysts anticipate that Amgen Inc. will post 22.78 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. Amgen’s dividend payout ratio is currently 62.65%.

Insider Activity

In related news, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This represents a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on AMGN shares. Oppenheimer boosted their price objective on shares of Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Guggenheim increased their target price on shares of Amgen from $343.00 to $388.00 and gave the stock a “neutral” rating in a research note on Monday, August 10th. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Weiss Ratings raised shares of Amgen from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 6th. Finally, Mizuho upped their price objective on shares of Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $379.36.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen was highlighted as one of the best-performing U.S. large-cap drugmakers in 2026, outperforming peers Merck and Pfizer despite lacking an obesity drug. The comparison reinforces investor confidence in Amgen’s existing portfolio and operating execution. Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?
• Positive Sentiment: Healthcare-sector strength and a rotation toward profitable drugmakers helped lift Amgen, while renewed enthusiasm for biotechnology also improved sentiment across the industry. Amgen Stock Surges as Healthcare Hits Record High
• Positive Sentiment: Argus raised its Amgen price target from $375 to $460 and maintained a “buy” rating, citing additional upside for the shares. Argus price-target update
• Neutral Sentiment: Amgen’s latest quarterly results beat consensus estimates for earnings and revenue, with revenue growth accelerating year over year. Full-year earnings guidance and expectations for continued growth remain important supports for the investment case.
• Neutral Sentiment: The obesity-drug market is becoming more selective, and Amgen is reportedly trimming some early-stage efforts. This could improve capital discipline, but it also highlights execution risk as the company competes in a crowded field. Obesity investing’s way forward, mapped
• Negative Sentiment: Although Cantor Fitzgerald and Mizuho raised their price targets, both retained “neutral” ratings and set targets below the current trading level, signaling valuation concerns after Amgen’s strong run. Analyst price-target updates

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.